Significant factors identified by univariate and multivariable Cox time-independent analysis for SDI progression in 5 years: baseline SLEDAI-2K 8 or 9, SLEDAI-2K ≥ 10, versus 6 or 7.
| Univariate Analysis | Multivariable Analysis | |||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Sex (male vs female) | 1.02 (0.64–1.64) | 0.9259 | ||
| Age at study start | 1.02 (1.01–1.03) | < 0.0001 | 1.03 (1.02–1.04) | < 0.0001 |
| White vs non-white | 1.15 (0.85–1.56) | 0.3671 | ||
| Disease duration at study entry | 1.01 (1–1.03) | 0.1382 | ||
| Study starting date after year 2000 vs before | 0.74 (0.56–0.97) | 0.0274 | 0.66 (0.50–0.88) | 0.0054 |
| SDI score at study entry | 1.15 (1.05–1.25) | 0.0014 | 1.03 (0.94–1.13) | 0.4715 |
| Antimalarials (yes vs no) at study entry | 0.92 (0.7–1.21) | 0.5551 | ||
| Immunosuppressants (yes vs no) at study entry | 1.31 (0.99–1.74) | 0.0613 | 1.59 (1.17–2.17) | 0.0032 |
| Entry SLEDAI-2K 8 or 9 vs entry SLEDAI-2K 6 or 7 | 1.12 (0.67–1.88) | 0.6663 | 1.15 (0.69–1.93) | 0.589 |
| Entry SLEDAI-2K ≥ 10 vs entry SLEDAI-2K 6 or 7 | 1.70 (1.13–2.56) | 0.011 | 1.91 (1.26–2.90) | 0.0021 |